E-LIB Suche - Ergebnisse für: Batlle-López, A.

1

439: Effects of the histone deacetylase inhibitor romidepsi..:

Cortiguera, M.G. ; García-Gaipo, L. ; Batlle-López, A..
European Journal of Cancer. 50 (2014) - p. S106 , 2014

2

Features of immune mediated diseases in JAK2 (V617F)-positi..:

Álvarez-Reguera, Carmen ; Prieto-Peña, Diana ; Herrero-Morant, Alba...
European Journal of Internal Medicine. 123 (2024) - p. 102-106 , 2024

Link: https://doi.org/10.1016/..

3

COVID-19 mRNA Based Vaccine Immune-Response Assessment in N..:

San Segundo, David ; Comins-Boo, Alejandra ; Lamadrid-Perojo, Patricia...
Vaccines. 9 (2021) 12 - p. 1429 , 2021

Link: https://doi.org/10.3390/..

4

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G. ; García-Gaipo, Lorena ; Wagner, Simon D....
Scientific Reports. 9 (2019) 1 - p. , 2019

Link: https://doi.org/10.1038/..

5

Patients with chronic lymphocytic leukemia and complex kary..:

Puiggros, Anna ; Collado, Rosa ; Calasanz, Maria José...
Oncotarget. 8 (2017) 33 - p. 54297-54303 , 2017

Link: https://doi.org/10.18632..

6

Stratifying diffuse large B-cell lymphoma patients treated ..:

Batlle-López, Ana ; de Villambrosía, Sonia González ; Francisco, Mazorra...
Oncotarget. 7 (2016) 14 - p. 18036-18049 , 2016

Link: https://doi.org/10.18632..

7

MYC as therapeutic target in leukemia and lymphoma:

Leon, Javier ; Cortiguera, Maria G ; Batlle-López, Ana..
Blood and Lymphatic Cancer: Targets and Therapy. , 2015

Link: https://doi.org/10.2147/..

8

The epigenetic regulator CTCF modulates BCL6 in lymphoma:

Batlle-López, Ana ; Cortiguera, María G. ; Delgado, M. Dolores
Oncoscience. 2 (2015) 10 - p. 783-784 , 2015

Link: https://doi.org/10.18632..

9

Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): A..:

Pérez-Rodríguez, Almudena ; Lourés, Esther ; Rodríguez-Trillo, Ángela...
Thrombosis Research. 134 (2014) 6 - p. 1171-1175 , 2014

Link: https://doi.org/10.1016/..

10

High p27 protein levels in chronic lymphocytic leukemia are..:

Caraballo, Juan M. ; Acosta, Juan C. ; Cortés, Miguel A....
Oncotarget. 5 (2014) 13 - p. 4694-4708 , 2014

Link: https://doi.org/10.18632..

11

R-COMP versus R-CHOP as first-line therapy for diffuse larg..:

Sancho, J.M ; Fernández-Alvarez, R ; Gual-Capllonch, F...
http://zaguan.unizar.es/record/100714. , 2021

Link: http://zaguan.unizar.es/..

12

MYC as therapeutic target in leukemia and lymphoma:

Cortiguera MG ; Batlle-López A ; Albajar M..
http://www.dovepress.com/myc-as-therapeutic-target-in-leukemia-and-lymphoma-peer-reviewed-article-BLCTT. , 2015

Link: https://doaj.org/article..

13

R-COMP versus R-CHOP as first-line therapy for diffuse larg..:

Sancho, Juan-Manuel ; Fernández-Alvarez, Rubén ; Gual-Capllonch, Francisco...
Cancer Medicine. , 2021

Link: https://ddd.uab.cat/reco..

14

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G ; García-Gaipo, Lorena ; Wagner, Simon D...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848194/. , 2019

Link: http://www.ncbi.nlm.nih...

15

Suppression of BCL6 function by HDAC inhibitor mediated ace..:

Cortiguera, María G ; García-Gaipo, Lorena ; Wagner, Simon D...
#PLACEHOLDER_PARENT_METADATA_VALUE#. , 2019

Link: http://hdl.handle.net/10..